Literature DB >> 10783317

Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522.

H Sasai1, M Masaki, K Wakitani.   

Abstract

Mutations of the adenomatous polyposis coli gene (Apc) have been implicated in the occurrence of sporadic colon cancer. Various Apc knockout strains of mice have been created to better understand the function of this gene. In the present study, using gene targeting, we disrupted the mouse Apc gene at the end of exon 10 to compare its effect with the effects of other types of Apc gene disruption, all of which are on exon 15. The mice expressed a mutant form of mRNA that encoded 474 amino acids instead of 2845 amino acids due to exon duplication. In addition, these Apc(Delta474) knockout mice developed intestinal and mammary tumors. Since the most severe cases of familial adenomatous polyposis are associated with mutations on exon 15, our mutation at exon 10 was expected to result in a mild phenotype. However, the number of polyps that our mice developed was similar to that of other Apc knockout mice such as Apc(Min) and Apc(1309) mice. Cyclooxygenase-2 (COX-2) has been implicated in colorectal carcinoma. Apc(Delta474) mice treated with JTE-522, a novel COX-2-selective inhibitor, showed a significantly reduced number of polyps. These results suggest that COX-2 plays an important role in polypogenesis and COX-2-selective inhibitors can be used as new preventive therapeutics against colorectal tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783317     DOI: 10.1093/carcin/21.5.953

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  19 in total

1.  Perils of immunohistochemistry: variability in staining specificity of commercially available COX-2 antibodies on human colon tissue.

Authors:  Harinder Garewal; Lois Ramsey; Ronnie Fass; Nancy K Hart; Claire M Payne; Harris Bernstein; Carol Bernstein
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

2.  Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.

Authors:  Takeo Iwama; Takayuki Akasu; Joji Utsunomiya; Tetsuichiro Muto
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

3.  The armadillo repeat domain of Apc suppresses intestinal tumorigenesis.

Authors:  Richard C Crist; Jacquelyn J Roth; Amy A Baran; Benjamin J McEntee; Linda D Siracusa; Arthur M Buchberg
Journal:  Mamm Genome       Date:  2010-10-01       Impact factor: 2.957

Review 4.  Understanding phenotypic variation in rodent models with germline Apc mutations.

Authors:  Maged Zeineldin; Kristi L Neufeld
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

Review 5.  Animal models of colorectal cancer.

Authors:  Robert L Johnson; James C Fleet
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

Review 6.  More than two decades of Apc modeling in rodents.

Authors:  Maged Zeineldin; Kristi L Neufeld
Journal:  Biochim Biophys Acta       Date:  2013-01-17

Review 7.  APC and its modifiers in colon cancer.

Authors:  Lawrence N Kwong; William F Dove
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 8.  Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.

Authors:  Denis E Corpet; Fabrice Pierre
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

Review 9.  Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice.

Authors:  Chinthalapally V Rao; Hiroshi Y Yamada; Yixin Yao; Wei Dai
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

Review 10.  Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.

Authors:  Takashi Fujimura; Tetsuo Ohta; Katsunobu Oyama; Tomoharu Miyashita; Koichi Miwa
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.